• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Novartis Invests in Historically Black Med Schools to Advance Trial Diversity

Novartis Invests in Historically Black Med Schools to Advance Trial Diversity

June 27, 2022

Novartis has committed $17.7 million to establish clinical trial centers at three historically black medical schools in an effort to help increase diversity, equity and inclusion in clinical research.

Under its Beacon of Hope program, the company will allocate funds for the creation of clinical trial centers of excellence at Charles R. Drew University of Medicine and Science in Los Angeles, Howard University College of Medicine in Washington, D.C. and Meharry Medical College in Nashville, where trials of underrepresented populations will be conducted by racially diverse investigators and site staff.

“Not only do we have to expand our faculty of experts, but we also have to train and put in play a future pipeline of scientists to lead that process. The ability to do that rests, of course, on having resources; this grant from the Novartis U.S. Foundation allows us to continue to build out those resources,” said Hugh Mighty, dean of Howard University College of Medicine.

Pharma giants Merck and Sanofi are also participating in Novartis’ initiative, vowing to run trials through the three newly announced centers and an additional center at Morehouse School of Medicine in Atlanta that is now operational and gearing up to initiate its first trial. Last July, Novartis pledged about $13.7 million to that school to set up a clinical trial center of excellence and two additional digitally enabled research centers.

The Beacon of Hope program has committed more than $50 million over 10 years, according to the company.

 

To view more CenterWatch Weekly stories, click here.

Upcoming Events

  • 15Sep

    Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

  • 16Oct

    WCG MAGI's Clinical Research Conference 2022 West

  • 16Nov

    17th Annual FDA Inspections Summit

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Options-360x240.png

    Cancer Patients Signal Interest in Less Travel, More Remote Trial Options

  • SurveywBlueBackground-360x240.png

    New Study Shows Trends in Funding, Racial Balance Amidst COVID-19

  • Complexity-360x240.png

    Rising Trial Complexities Create More Payment Problems, Frustrations for Sites

  • Challenge-360x240.png

    BYOD Trials Growing in Popularity, But Unique Tech Challenges Remain

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing